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Abstract 
Background: A basic fibroblast growth factor (bFGF) slow-release system was combined to  
a biodegradable nerve conduit with the hypothesis this slow-release system would increase the 
capacity to promote nerve vascularization and Schwann cell proliferation in a rat model.  
Materials and Methods: Slow-release of bFGF was determined using ELISA.  A total of 60 
rats were used to create a 10 mm gap in the sciatic nerve.  A polyglycolic acid-based nerve 
conduit was used to bridge the gap, either without or with a bFGF slow-release incorporated 
around the conduit (n=30 in each group).  At 2 (n=6), 4 (n=6), 8 (n=6), and 20 (n=12) weeks 
after surgery, samples were resected and subjected to histological, immunohistochemical, and 
transmission electron microscopic evaluation for nerve regeneration.  Results: Continuous 
release of bFGF was found during the observation period of 2 weeks.  After in vivo 
implantation of the nerve conduit, greater endothelial cell migration and vascularization resulted 
at 2 weeks (Proximal: 20.0±2.0 vs.12.7±2.1, p=0.012, Middle: 17.3±3.5 vs.8.7±3.2, 
p=0.034).  Schwann cells showed a trend toward greater proliferation and axonal growth had 
significant elongation (4.9±1.1 mm vs. 2.8±1.5 mm, p=0.049) at 4 weeks after implantation.  
The number of myelinated nerve fibers, indicating nerve maturation, were increased 20 weeks 
after implantation (Proximal: 83.3±7.5 vs.53.3±5.5, p=0.065, Distal: 71.0±12.5 vs.44.0±
11.1, p=0.0491).  Conclusion: These findings suggest that the bFGF slow-release system 
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Introduction 
In the treatment of peripheral neurological deficits, autologous nerve grafting is the first 
choice.  The sural nerve, antebrachial cutaneous nerve, terminal branch of posterior 
interosseous nerve, and other choices are commonly used, however, loss of function and 
potential morbidity from creation of these donor sites are undesirable effects of their use.  In 
recent years, synthetic nerve conduits and allogeneic nerve grafting materials have been 
introduced into clinical practice as alternatives to autologous nerve grafting.1-3)  
The first attempt at nerve conduit applied for nerve regeneration used silicone tubes.4) 
Subsequent studies explored biodegradable materials with open internal structure as the conduit.  
More recently, filling the conduit with a regeneration-conducive material such as collagen 
demonstrated improved nerve regeneration, however, the outcome remained inferior to 
autologous nerve grafting and allogeneic nerve transplantation.5-7)   
An adequate blood supply to the nerve is important to promote nerve regeneration.8)   
Basic fibroblast growth factor (bFGF) is a cytokine that accelerates angiogenesis.9)   If an 
angiogenic stimulus can be induced at the nerve transection sites which are replaced with the 
biodegradable nerve conduit by bFGF, then nerve regeneration is speculated to accelerate.  
However, bFGF has a short half-life (T1/2 = 1.5 minutes) and is dispersed within the body 
quickly.  To compensate for this shortcoming, Tabata and colleagues developed a bFGF 
slow-release system using gelatin microspheres as a carrier to facilitate continuous bFGF 
administration at the site of application.10)  
In this study, we combined bFGF slow-release system using gelatin to a biodegradable nerve 
conduit with the hypothesis that the bFGF slow-release system would promote vascularization, 
endothelial cell and Schwann cell proliferation, and the subsequent axonal elongation through 
the nerve conduit in a rat model.  
 
Materials and Methods 
All the animal experiments were conducted following the regulations of the Animal 
Experiment Committee of Kindai University.  Fourteen-week-old SD rats (mean body weight 
280~324 g Harlan Sprague Dawley, Indianapolis, IN, USA) were used as experimental animals 
(n = 60).  Housing was maintained in a clean rack with uniform temperature (22°C) and 
humidity (50%) and 12-hour light-dark cycle.  Radiation-sterilized (3 mG) solid food and 
water was provided ad libitum.  
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1) Creation of biodegradable nerve conduit with bFGF slow-release system 
A nerve conduit made of biodegradable material (Nerbridge®, 1.5 mm in diameter, 12 mm 
in length, Toyobo Co., Ltd., Osaka) was used.  Onto this biodegradable nerve conduit, the 
bFGF-impregnated gelatin microspheres were applied uniformly using a micro-pipette. The 
bFGF slow-release system using gelatin microspheres (60 μg bFGF/60 μL PBS mixed with 6 
mg gelatin) was prepared according to the method of Tabata and colleagues.10)   The 
bFGF-containing gelatin microsphere-applied biodegradable nerve conduit was immersed in 
PBS (pH 7.4, 37°C, 10 mL), and 100 μL of supernatant was collected at 1 hour and on 2, 4, 6, 8, 
10, 12 and 14 days after immersion.  The amount of bFGF contained in the supernatant was 
determined by ELISA analysis for bFGF (RayBio Human bFGF ELISA Kit).  
2) Scanning electron microscopy of the biodegradable nerve conduit surface 
Observation of the surface of biodegradable nerve conduit after preparation of the bFGF 
slow-release system (as above) was conducted using scanning electron microscopy.  The 
samples were dried and gold-coated with evaluation using scanning electron microscope (S-900, 
Hitachi, Ltd., Japan).11)  
3) Establishment of nerve defect model and experimental design 
After general anesthesia with urethane and α-chloralose, a 10-mm gap was created by sharp 
transection of the sciatic nerve on one leg per rat.  The ends of the nerve were drawn into the 
open ends of the 12 mm long biodegradable nerve conduit by 1 mm on each side, using a 
horizontal mattress stitch of 10-0 nylon suture to secure each end in place.  Two study groups 
were used, one with the bFGF slow-release system (nerve conduit+60 μg-bFGF, n=30) and a 
control group (nerve conduit only, n=30).  In the nerve conduit+60 μg-bFGF group, the 
bFGF-containing gelatin microspheres were applied after implanting the conduit in place (n=30), 
whereas the control group had no further treatment after conduit implantation (n=30).  Harvest 
of the implanted nerve conduit in each group was done 2 (n=6), 4 (n=6), 8 (n=6) and 20 (n=12) 
weeks after the surgery (Figure 1).  
4) Evaluation of the nerve growth rate using immunohistological method 
After harvest, the tissues collected at 2, 4, 8, 20 weeks (n=6 at each point in each group) 
after implantation were immersion-fixed in 10% neutral buffered formalin solution for 3 days.  
Paraffin blocks were prepared and 5-μm sections were made in the longitudinal direction with a 
microtome (LEICA SM2000R).  Anti-CD31 antibody (anti-CD31 Rabbit polyclonal 
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antibodies: Abcam, ab28364) was used for staining vascular endothelial cells, anti-S100 
antibody (anti-S100 Rabbit polyclonal antibodies: Dako, Z0311) was used for staining Schwann 
cells, and anti-NF antibody (anti-neurofilament 68 kDa-Mouse monoclonal antibodies: Dako, 
M0762) was used for staining axons.  In the staining of vascular endothelial cells using CD31 
antibody, the number of blood vessels in 3 regions, the proximal region (peripheral side 2.5 mm 
from the stump of proximal side), middle region and distal region (proximal side 2.5 mm from 
the stump of distal side) of the biodegradable nerve conduit was counted. Three visual fields of 
in each group were photographed, and the mean value per unit area (50 μm × 30 μm , 1,500 
μm2) was calculated for number of blood vessels including capillaries.  Image J software 
(National Institutes of Health, MD, USA) was used for analysis.  
The migration distance of Schwann cells (S100 antibody) from the proximal and distal sides 
of the biodegradable nerve conduit was determined.  The distance of axonal elongation 
(anti-NF antibody) from the proximal nerve stump to the inside of the biodegradable nerve 
conduit was determined.  The distances of Schwann cell migration and axonal elongation were 
determined by Image J software. 
5) Evaluation of nerve maturity using transmission electron microscopy (TEM) 
 To study nerve maturity, TEM images of myelinated nerve fibers for number and the 
cross-sectional area were evaluated at 20 weeks (n=6 in each group) after implantation.  
Contralateral native sciatic nerves (n=6 in each group) were transected for comparison with the 
other two groups.  Biodegradable nerve conduits and native sciatic nerves were immersed and 
fixed in 4% glutaraldehyde for 3 days.  The tissues were sectioned (1.5-μm thick) transversely 
with an ultra-microtome (LEICA EM UC7) and then post-fixed with 4% osmium.  The slices 
were dehydrated by alcohol series, stained with uranium and embedded in epon.  They were 
sliced to ultrathin sections of 700 A in thickness, stained with uranyl and lead acetate and 
observed using a transmission electron microscope (H-7700, Hitachi, Ltd., Japan).  The sites 
observed were the proximal, middle and distal regions of biodegradable nerve conduit and were 
observed at the maximum scale possible to identify axons, 50 μm × 40 μm (= 2,000 μm2).  
Three (3) visual fields near the center of each cross-section in each group were photographed, 
and the mean value per unit area of 2,000 μm2 was calculated for number and the cross-sectional 
area of myelinated nerve fibers.  Image J software was used for analysis.  
6) Statistical analysis 
All experimental results were indicated as mean ± standard error (SE).  Statistical analyses 
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used Student t-test for comparison between two groups and by one-way analysis of variance 
(one-way ANOVA) and Holm post-test for comparison among 3 or more groups (different levels 
of the nerve).  Data analysis was conducted using GraphPad Prism (GraphPad Software Inc., 
San Diego, CA, USA), and P<0.05 was used as the criterion for significance.  
 
Results 
1) bFGF amount in slow-release system and localization of gelatin microspheres in 
biodegradable nerve conduit 
The surface of the nerve conduit showed that the gelatin microspheres were localized along 
the outer surface of biodegradable nerve conduit, with some of the microspheres leaching into 
the adjacent surrounding tissues (Figure 2A, B). The amount of bFGF released from the 
prepared conduits was determined by the ELISA method.  The release rate was constant, with 
64.9% of the total bFGF released over 14 days.  Moreover, accumulation of bFGF was 
maintained at about 5 μg/day (Figure 2C).   
2) Findings of gross examination after implantation of the conduit 
The control conduits maintained a clear profile within the tissue bed, with little evidence of 
integration with the surrounding tissue.  The wall of the conduits also became thinner by 20 
weeks after implantation.  In contrast, the conduits in the nerve conduit+60 μg-bFGF group 
became covered by and subsequently buried within the surrounding tissues, with clear 
integration and thickening (Figure 3).   
3) Evaluation of the nerve growth rate using immunohistochemical method 
The time course of the development of blood vessels in three regions (proximal, middle and 
distal regions) of the biodegradable nerve conduit was examined (Figures 4, 5 and 6).  Blood 
vessel significantly increased by 2 weeks in the proximal (20.0±2.0 vs. 12.7±2.1, p=0.012) 
and middle (17.3±3.5 vs. 8.7±3.2, p=0.034) regions of the nerve conduit+60 μg-bFGF group, 
compared with controls (Figure 4 and 6).  By 4 weeks, the control group had achieved similar 
numbers as the nerve conduit+60 μg-bFGF group in the proximal and middle portions (Figure 5 
and 6), but the distal region showed significantly increased blood vessels in the nerve 
conduit+60 μg-bFGF group (27.3±2.1 vs. 10.7±1.5, p=0.003).  At 20 weeks, the blood 
vessel channels had decreased in the proximal and middle regions of both groups.  In contrast, 
for the distal region, the control group had significantly increased blood vessel numbers (32.0±
2.0 vs. 15.7±2.1, p=0.001), whereas these numbers had decreased in the nerve conduit+60 
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μg-bFGF group (Figure 6).  These results support trends for both more rapid development of 
blood vessel and subsequent maturation of these channels (seen as a pruning of channels within 
the nerve space).    
Migration of Schwann cells from both ends of proximal and distal regions of biodegradable 
nerve conduit was observed in both groups, showing a progressive pattern from 2 (22.0±3.6 vs. 
13.5±0.9, p=0.029) to 4 weeks and with complete extension by 8 weeks.  The Schwann cell 
migration-tip had apparently extended farther in the nerve conduit+60 μg-bFGF group at 2 
weeks (Figures 7 and 8).  
Axonal elongation from the proximal region of biodegradable nerve conduit was observed 
in both groups, with axons extending to the distal region by 20 weeks.  This axonal elongation 
appeared to be more advanced at the earlier time points (4.9±1.1 mm vs. 2.8±1.5, p=0.049 at 
weeks) in the nerve conduit+60 μg-bFGF group (Figures 9 and 10). 
The ratio of average axonal elongation distance between the nerve conduit+60 μg-bFGF and 
control group was summarized in Table 1.  When the bFGF slow-release system was 
combined to a biodegradable nerve conduit, the migration distance of vascular endothelial cells 
and the number of blood vessels are promoted in the early phase (2-4 weeks) of nerve 
regeneration process, and the subsequent distances of Schwann cells were extended.  Finally, 
axon elongated 1.7 times at 4 weeks after implantation (Table 1), and the nerve regeneration 
was clearly improved. 
4) Nerve maturity at 20 weeks assessed by TEM 
The number of myelinated nerve fibers significantly increased in the proximal (83.3±7.5 vs. 
55.3±5.5, p=0.0065) and distal (71.0±12.5 vs. 44.0±11.1, p=0.0491) regions in the nerve 
conduit+60 μg-bFGF group (Figures 11 and 12).  The myelinated nerve fiber area in the nerve 
conduit+60 μg-bFGF group was comparable with that of the native sciatic nerve at proximal and 
middle regions, and it was significantly higher at the distal region (243.3±29.4 vs. 128.1±7.1, 
p=0.0259) (Figure 13).  Our results demonstrated that the number and area of myelinated 
nerve fibers were increased, indicating nerve maturation by bFGF slow-release system. 
 
Discussion 
Biodegradable nerve conduits present an attractive alternative to autologous nerve grafting.  
These conduits use a hollow tube structure of various composition such as polyglycolic acid 
(PGA), poly lactide-caprolactone (P(LA-CL), or collagen of bovine or porcine origin, to allow 
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nerve regeneration through the channel.  Though in use, variable outcomes have been 
reported.3, 12-16   The nerve conduit tested in the present experiment is of the biodegradable 
material obtained by forming PGA fiber to a luminal structure of which the thickness of luminal 
wall was adjusted to about 500 μm.  Different from the biodegradable nerve conduit having 
conventional hollow structure, the inner lumen is filled with type I and III collagen sponge, and 
the outer surface is covered with collagen of the same composition.  It is reported that the 
collagen sponge in the inner lumen becomes the scaffold in migration and growth of various 
cells contributing to nerve regeneration and the nerve regeneration is promoted.17-19) 
As concerns regeneration of peripheral nerve, the 3-stage regeneration mechanism shown 
below has been reported; firstly, the damaged nerve becomes hypoxic, and macrophages migrate 
and secrete vascular endothelial growth factor A (VEGF-A).  Secondly, the vascular 
endothelial cells migrate in the nerve tissues, and pillared vessels are formed in the direction of 
nerve tract.  Finally, Schwann cells migrate along the formed vessels, and axons regrow. 20)  In 
the process of nerve regeneration, therefore, the angiogenesis prior to nerve regeneration is 
considered very important.  Though 10 mm is considered as the critical deficit of nerve 
regeneration, it was possible to regenerate the nerve in 25-mm rat sciatic nerve deficit when the 
blood vessel was induced into the inner lumen of nerve conduit.21)   From the histological 
evaluation, muscle weight and electrophysiological study, nerve regeneration was more 
accelerated by placing the blood vessel close to the lateral surface of nerve conduit if the 
low-molecular-weight molecules such as albumin are able to penetrate through the nerve 
conduit wall.19)   In this research, the bFGF slow-release system was combined for the purpose 
of creating more vascular networks around the biodegradable nerve conduit of which the 
permeability of albumin molecule through the luminal wall has already been confirmed. 17) 
bFGF has the important functions by acting on the vascular endothelial cells and vascular 
smooth muscle cells, proliferating them, adjusting the expression of both VEGF and HGF 
factors to promote angiogenesis.  Moreover, it was reported that the effect is higher than 
VEGF and platelet-derived growth factor (PDGF).9), 22)    When bFGF is administered alone, the 
biological activity is very short as 90 seconds of blood half-life, however, control release of 
bFGF can be obtained if bFGF is combined with gelatin microspheres.  In this bFGF 
slow-release system, bFGF and acidic gelatin microspheres adsorb and immobilize 
electrostatically by interaction.   According to the degradation rate of gelatin, bFGF is released 
slowly and the pharmacological activity of bFGF can be maintained. 10)   
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This bFGF slow-release system has already been applied clinically for the surgical 
treatment of finger-tip amputation.   Marked therapeutic effects have been reported when the 
optimal bFGF concentration of 2~10 μg/cm2/day in tissues was maintained.23)    For the bFGF 
slow-release system using gelatin microspheres, it was reported that the strongest angiogenesis 
was observed in vivo when the initial concentration of bFGF was set at 1 mg/mL.24)   In this 
study, the bFGF slow-release system with the initial concentration of 1 mg/mL (actual dosage of 
bFGF: 60μg, gelatin: 6 mg) was applied outside the biodegradable nerve conduit.  Based on a 
result of examination using the ELISA, it was confirmed that the bFGF concentration was kept 
at about 5 μg/day during the observation period for 2 weeks.  The in vivo study demonstrated 
that the migration distance for both vascular endothelial cells and Schwann cells, and the 
elongation distance of axons was greater in the nerve conduit+60 μg-bFGF group in the early 
phase of nerve regeneration (within 4 weeks after implantation).   To our knowledge, this is 
the first report which has shown evidence that the vascular network formed in the surrounding 
environment of a biodegradable nerve conduit by bFGF slow-release system has a strong 
influence on both angiogenesis and the subsequent nerve regeneration in a rat model.  Though 
the axonal elongation in rats is faster (approximately 3-4 mm/day) while it is 2-4 fold 
slower in humans25), a bFGF slow-release system offers a promising technique to enhance 
nerve regeneration with biodegradable nerve conduits in the clinical setting.   
Currently, there is a growing interest in the clinical potential of mesenchymal stem 
cells derived from bone marrow26)、adipose tissue27),28)、and menstrual blood29).  Among 
these, bone marrow stem cells are reported to enhance neovascularization by producing 
angiopoietin-1 and 230).  After being implanted into nerve conduits, bone marrow stem 
cells have been reported to show their remarkable proliferative capacity by producing 
neurotrophic factors and by differentiating into Schwann cell-like cells31),32). The 
utilization of stem cells into biodegradable nerve conduits with FGF slow-release 
system is therefore an important step toward new methods to enhance peripheral nerve 
repair.   
It is clinically accepted that a biodegradable nerve conduit is indicated for a nerve gap 
length being less than 2 cm, while the majority of peripheral nerve gap length in human 
measures around 3-5 cm 33).  In order to accelerate axonal regrowth and later 
myelination of a biodegradable nerve conduit, approach using stem cells and bFGF 
slow-release system is considered one of the promising methods.   
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The limitation of this study is the lack of a positive control such as a group with the 
nerve autograft and functional assessment such as electrophysiological evaluation.  In the 
field of nerve regeneration, axon, action potential, and the gait needs to be recovered to almost 
the same level as those of autologous nerve transplantation when the biodegradable nerve 
conduit is used.34-36)   Though the sufficient number and area of myelinated nerve fibers were 
observed by the introduction of bFGF slow-release system, the evaluation on motor function is 
not still clear.  The future study on motor function is scheduled.  
 
Conclusion 
These findings suggest that the bFGF slow-release system acts on both endothelial cells and 
Schwann cells to improve axonal elongation through a biodegradable nerve conduit. 
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Figures and tables 
 
Figure 1:  Experimental protocol 
 
Figure 2:  Scanning electron microscopic findings 
Panel A showed biodegradable nerve conduit (control), while panel B showed biodegradable 
nerve conduit with the bFGF slow-release system (experimental group).  Panel C showed 
slowly released bFGF level (bFGF level per day) determined by the ELISA method.  
  
Figure 3:  Gross examination after implantation of the conduit 
To the sciatic nerve gap, the biodegradable nerve conduit with the bFGF slow-release system 
(experimental group) and the control biodegradable nerve conduit were implanted.  Gross 
examination was conducted over time.  P: Proximal region, D: Distal region.  
 
Figure 4:  Histological evaluation of blood vessels using immunohistochemistry 
The time course of the development of blood vessels in three regions (proximal, middle and 
distal regions) of the nerve conduit+60 μg-bFGF group was examined. 
 
Figure 5:  Histological evaluation of blood vessels using immunohistochemistry 
The time course of the development of blood vessels in three regions (proximal, middle and 
distal regions) of the nerve conduit group was examined. 
 
Figure 6: Quantitative evaluation of angiogenesis 
The number of blood vessels indicated by CD31-staining per 1,500 μm2 in the biodegradable 
nerve conduit was counted and compared between the nerve conduit+60 μg-bFGF group and the 
nerve conduit group.   
 
Figure 7: Immunohistochemical evaluation of Schwann cells  
Migration of Schwann cells from both ends of proximal (left) and distal region (right) was 
evaluated by S100-staining.  
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Figure 8:  Quantitative evaluation of Schwann cells in the biodegradable nerve conduit 
 
Figure 9:  Immunohistochemical evaluation of axon 
Axonal elongation from the proximal region was evaluated by NF-staining. 
  
Figure 10:  Quantitative evaluation of axons in the biodegradable nerve conduit 
 
Figure 11:  Nerve maturity at 20 weeks assessed by transmission electron microscope 
 
Figure 12:  Quantitative evaluation of myelinated nerve fiber numbers 20 weeks after 
implantation 
Total number of myelinated nerve fiber in 2,000 μm2 in the proximal region (left), middle region 
(center), and distal region (right) was quantitatively evaluated.  
 
Figure 13:  Quantitative evaluation of the myelinated nerve fiber area 20 weeks after 
implantation 
Total area of myelinated nerve fiber in 2,000 μm2 in the proximal region (left), middle region 
(center), and distal region (right) was quantitatively evaluated.  
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